HomeCompareABT vs HRC

ABT vs HRC: Dividend Comparison 2026

ABT yields 2.36% · HRC yields 11.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HRC wins by $1.72M in total portfolio value
10 years
ABT
ABT
● Live price
2.36%
Share price
$101.89
Annual div
$2.40
5Y div CAGR
63.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$533.6K
Annual income
$328,772.04
Full ABT calculator →
HRC
HRC
● Live price
11.38%
Share price
$155.96
Annual div
$17.74
5Y div CAGR
40.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.26M
Annual income
$1,423,429.65
Full HRC calculator →

Portfolio growth — ABT vs HRC

📍 HRC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABTHRC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABT + HRC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABT pays
HRC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABT
Annual income on $10K today (after 15% tax)
$200.23/yr
After 10yr DRIP, annual income (after tax)
$279,456.23/yr
HRC
Annual income on $10K today (after 15% tax)
$966.88/yr
After 10yr DRIP, annual income (after tax)
$1,209,915.20/yr
At 15% tax rate, HRC beats the other by $930,458.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABT + HRC for your $10,000?

ABT: 50%HRC: 50%
100% HRC50/50100% ABT
Portfolio after 10yr
$1.40M
Annual income
$876,100.84/yr
Blended yield
62.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABT right now

ABT
Analyst Ratings
30
Buy
10
Hold
Consensus: Buy
Price Target
$137.67
+35.1% upside vs current
Range: $120.00 — $158.00
Altman Z
4.9
Piotroski
6/9
HRC
Analyst Ratings
7
Buy
12
Hold
1
Sell
Consensus: Hold
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABT buys
0
HRC buys
0
No recent congressional trades found for ABT or HRC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABTHRC
Forward yield2.36%11.38%
Annual dividend / share$2.40$17.74
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR63.2%40.3%
Portfolio after 10y$533.6K$2.26M
Annual income after 10y$328,772.04$1,423,429.65
Total dividends collected$492.4K$2.14M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyHold

Year-by-year: ABT vs HRC ($10,000, DRIP)

YearABT PortfolioABT Income/yrHRC PortfolioHRC Income/yrGap
1← crossover$11,084$384.43$12,296$1,595.93$1.2KHRC
2$12,510$649.94$15,730$2,573.05$3.2KHRC
3$14,505$1,118.82$21,147$4,316.00$6.6KHRC
4$17,499$1,978.53$30,235$7,608.15$12.7KHRC
5$22,364$3,640.59$46,615$14,263.36$24.3KHRC
6$31,026$7,096.70$78,712$28,834.27$47.7KHRC
7$48,215$15,016.56$148,063$63,841.01$99.8KHRC
8$87,182$35,592.30$315,890$157,462.80$228.7KHRC
9$191,446$98,161.15$778,498$440,495.17$587.1KHRC
10$533,619$328,772.04$2,256,422$1,423,429.65$1.72MHRC

ABT vs HRC: Complete Analysis 2026

ABTHealthcare

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Full ABT Calculator →

HRCStock

Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates in Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising Vest System, VitalCough System, MetaNeb System, Monarch, and Life2000 systems to assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include surgical tables, lights, and pendants; positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. Further, it is involved in the sales and rental of products to acute and extended care facilities through direct sales force and distributors; sales and rental of products directly to patients in the home; and sales to primary care facilities through distributors. Additionally, the company offers continuum of clinical care, including acute care and primary care, as well as clinical research organizations. Hill-Rom Holdings, Inc. was founded in 1969 and is headquartered in Chicago, Illinois.

Full HRC Calculator →
📬

Get this ABT vs HRC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABT vs SCHDABT vs JEPIABT vs OABT vs KOABT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.